Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma by Dimopoulos Meletios, Spencer Andrew, Attal Michael, Prince H Miles, Harousseau Jean-Luc, Dmoszynska Anna, San Miguel Jesus, Hellmann Andrzej, Facon Thierry, FoĆ  Robin, Corso Alessandro, Masliak Zvenyslava, Olesnyckyj Marta, Yu Zhinuan, Patin John, Zeldis Jerome B, Knight Robert D, Multiple Myeloma (010) Study Investigators in The New England journal of medicine (2007).

[PMID: 18032762] PubMed


Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.